FDG PET/CT for the detection and evaluation of breast diseases: usefulness and limitations.

Positron emission tomography (PET) with fluorine 18 fluorodeoxyglucose (FDG) is used to diagnose, stage, and monitor breast cancer. FDG PET has the capability to depict abnormal metabolic activity before any anatomic change occurs; however, in the absence of identifiable anatomic structures on PET images, it may be impossible to identify the location of areas of increased radionuclide uptake. In such cases, the coregistration of PET images with images from computed tomography (CT) may help improve diagnostic accuracy and lead to better clinical management of patients with breast cancer. Although FDG PET/CT may have limited diagnostic value for detecting small primary breast tumors, well-differentiated breast cancer, or regional lymph node involvement, it is superior to conventional imaging modalities for detecting distant metastases and recurrences and for monitoring the response to therapy.

[1]  G. Hortobagyi,et al.  Positron emission tomography with fluorine‐18‐deoxyglucose in the detection and staging of breast cancer , 1993, Cancer.

[2]  Lee P. Adler,et al.  Positron emission tomography and breast masses: Comparison with clinical, mammographic, and pathological findings , 1994, Annals of Surgical Oncology.

[3]  T. Yeatman,et al.  The significance of breast cancer lymph node micrometastases. , 1999, Surgical oncology clinics of North America.

[4]  David A Mankoff,et al.  Evolving role of positron emission tomography in breast cancer imaging. , 2005, Seminars in nuclear medicine.

[5]  R L Wahl,et al.  Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  D. Binns,et al.  Pattern of uptake and excretion of (18)F-FDG in the lactating breast. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  N. Cascinelli,et al.  Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. , 2001, Journal of the National Cancer Institute.

[8]  J. Carreras,et al.  Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. , 2002, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[9]  Torsten Mattfeldt,et al.  FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  M E Phelps,et al.  The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. , 1992, Annals of surgery.

[11]  A. Alavi,et al.  Fluorodeoxyglucose-PET in the management of breast cancer. , 2004, Radiologic clinics of North America.

[12]  R L Wahl,et al.  Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. , 1999, Radiographics : a review publication of the Radiological Society of North America, Inc.

[13]  J. Bergh,et al.  Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J L Sunshine,et al.  Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. , 1993, Radiology.

[15]  J. Czernin.  FDG-PET in breast cancer: a different view of its clinical usefulness. , 2002, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[16]  F. Jänicke,et al.  Comparison of fluorodeoxyglucose positron emission tomography and ‘conventional diagnostic procedures’ for the detection of distant metastases in breast cancer patients , 2002, Nuclear medicine communications.

[17]  R. Wahl,et al.  Detection of unexpected additional primary malignancies with PET/CT. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  F. Dehdashti,et al.  Whole-body positron emission tomography: normal variations, pitfalls, and technical considerations. , 1997, AJR. American journal of roentgenology.

[19]  M. Greco,et al.  Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  Claudio Landoni,et al.  PET/CT and breast cancer , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  R. Wahl,et al.  Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Wahl.  Targeting glucose transporters for tumor imaging: "sweet" idea, "sour" result. , 1979, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  A. Alavi,et al.  Clinicopathologic factors associated with false negative FDG–PET in primary breast cancer , 2006, Breast Cancer Research and Treatment.

[24]  R. Wahl,et al.  Initial experience with FDG-PET/CT in the evaluation of breast cancer , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  Thomas Beyer,et al.  Advantages and limitations of FDG PET in the follow-up of breast cancer , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  A. Ezzat,et al.  F-18 FDG uptake in breast infection and inflammation. , 2000, Clinical nuclear medicine.

[27]  M. Phelps,et al.  Performance of 2-Deoxy-2-[F-18]fluoro-d-glucose Positron Emission Tomography and Integrated PET/CT in Restaged Breast Cancer Patients , 2005, Molecular Imaging and Biology.

[28]  Thomas F Hany,et al.  Positron emission tomography and PET CT of the head and neck: FDG uptake in normal anatomy, in benign lesions, and in changes resulting from treatment. , 2002, AJR. American journal of roentgenology.

[29]  M Schwaiger,et al.  Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  U. Pietrzyk,et al.  Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability , 1996, European Journal of Nuclear Medicine.

[31]  M. Schwaiger,et al.  Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  P. F. Winter,et al.  Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry , 1996, European Journal of Nuclear Medicine.

[33]  H. Biersack,et al.  Locally advanced breast cancer: is PET useful for monitoring primary chemotherapy? , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  D W. Townsend,et al.  Combined PET/CT Imaging in Oncology. Impact on Patient Management. , 2000, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[35]  L. Weir,et al.  The Value of FDG Positron Emission Tomography in the Management of Patients with Breast Cancer , 2005, The breast journal.

[36]  Hans-Jürgen Gallowitsch,et al.  F-18 Fluorodeoxyglucose Positron-Emission Tomography in the Diagnosis of Tumor Recurrence and Metastases in the Follow-Up of Patients With Breast Carcinoma: A Comparison to Conventional Imaging , 2003, Investigative radiology.

[37]  R. Rubens,et al.  Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  David J. Yang,et al.  Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  R. Korn,et al.  Unexpected focal hypermetabolic activity in the breast: significance in patients undergoing 18F-FDG PET/CT. , 2006, AJR. American journal of roentgenology.

[40]  J. Nährig,et al.  Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Michael E Phelps,et al.  Relationship between 18F-FDG uptake and breast density in women with normal breast tissue. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  Ludwig G. Strauss,et al.  Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients , 1996, European Journal of Nuclear Medicine.

[43]  V. R. McCready,et al.  FDG accumulation and tumor biology. , 1998, Nuclear medicine and biology.

[44]  M. Phelps,et al.  Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.